Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-03
1997-06-03
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
056355157
ABSTRACT:
Cinchonine, dihydrocinchonine or hydroquinidine are used as multidrug resistance inhibiting substance in the treatment of cancerous tumors by the use of cytotoxic agents. Particularly, cinchonine, dihydrocinchonine or hydroquinidine are used in the preparation of pharmaceutical compositions used in the treatment of cancerous tumors developing the phenomenon of multidrug resistance. Application to the treatment of human cancers.
REFERENCES:
Chemotherapy of Cancer, 2nd Ed, Carter et al, John Wiley & Sons, N.Y., N.Y., 1981, pp. 90-91.
Molecular Pharmacology, vol. 33, No. 4, Apr. 1988, (US), J. M. Zamora et al.: "Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells", pp. 454-462, see abstract; pp. 457-458.
Proceedings of the 77th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, 7-10 May 1986, vol. 27, J. M. Zamora et al.: "Potentiation of Vinca alkaloid (VA) cytotoxicity by quinolines, acridines, indole alkaloids and aromatic amines", p. 395, abstract No.: 1567, see the whole document.
International Journal of Cancer, vol. 46, No.: 1, 15 Jul. 1990, (Lusanne, CH), J.F. Eliason et al.: "Human multi-drug-resistant cancer cells exhibit a high degree of selectivity for stereoisomers of verapamil and quinidine", pp. 113-117, see the whole document.
Tetrahedron Letters, vol. 27, No.: 49, 1986, (GB), R.T. Brown et al.: "Stereospecific synthesis of erythro Cinchona alkaloids from secologanin", pp. 6005-6008, see pp. 6005-6006.
H. Rimpler et al.: "Pharmazeutische Biologie II. Biogene Arzneistoffe", 1990, pp. 437-440; Cinchonae cortex, Georg Thieme Verlag, Stuttgart, DE, see pp. 439-440.
J.E.F. Reynolds et al.: "Martindale--The Extra Pharmacopoeia", 28th edition, 1982, p. 1378, The Pharmaceutical Press, London, GB, see monograph No.: 7786-v: Hydroquinidine hydrochloride.
S. Budavari et al.: "The Merck index", 11th edition, 1989, p. 356, Merck & Co., Rahway, NJ, US, see monograph No.: 2289: Cinchonine.
S. Budavari et al.: "The Merck index", 11th edition, 1989, p. 762, Merck & Co., Rahway, NJ, US, see monograph No.: 4736: Hydroquinidine.
Ann. 1st. Super. Sanita, vol. 21, No.: 3, 1985, (IT), D.C. Warhurst: "New drugs and their potential use against drug-resistant malaria", pp. 327-336, see abstract; pp. 328-329.
Nature, vol. 345, 17 May 1990, (London, GB), C. Newbold: "The path of drug resistance", pp. 202-203, see p. 202.
Annals of Tropical Medicine and parasitology, vol. 69, No.: 4, Dec. 1975 (Liverpool, GB), N.M. Mattock et al.: "The experimental chemotherapy of leishmaniasis. III. Detection of antileishmanial activity in some new synthetic compounds in a tissue culture model"; pp. 449-462, see p. 456.
Therapie, vol. 43, No.: 4, Jun./Jul. 1988, B. Flouvat et al.: "Metabolites de la dihydroquinidine observes apres administration a l'homme d'une formulation a liberation prolongee", pp. 255-261, see the abstract.
J. Chem. Soc. Perkin Trans. I, 1988, M. Ihara et al.: "Total synthesis of hydrocinchonidine and hydrocinchonine via photo-oxygenation of an indole derivative", pp. 1277-1281, see the abstract; schemes 1-4.
Chauffert Bruno
Genne Philippe
Gutierrez Gilles
Mauvernay Rolland-Yves
Debiopharm S.A.
Goldberg Jerome D.
LandOfFree
Therapeutic agents for the treatment of multiple drug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents for the treatment of multiple drug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents for the treatment of multiple drug resistance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-391939